Thyme Care

About Thyme Care

Thyme Care operates as a value-based care enabler focused on the oncology sector. Founded in 2020 by Robin Shah and Dr. Bobby Green, the company was established to address the fragmented and confusing experience patients face following a cancer diagnosis. The founders bring extensive experience from previous roles at Flatiron Health and OneOncology, combining business acumen with deep clinical expertise in oncology. Shah's journey in the field was inspired by helping his oncologist father's community practice, instilling a commitment to patient-focused care. The company partners with health plans, employers, and risk-bearing providers to improve health outcomes and reduce the total cost of care for cancer patients. Its business model is built on value-based arrangements, where revenue is generated from the savings achieved for its partners, aligning financial incentives with patient well-being. Thyme Care does not get paid if it does not generate savings. Thyme Care's offering combines a dedicated, technology-enabled Care Team—comprising oncology nurses and resource specialists—with a proprietary data analytics platform called Thyme Box. This platform integrates with existing clinical workflows to provide 24/7 virtual support, identify at-risk patients, guide interventions, and coordinate care among oncologists, surgeons, and primary care physicians. The model gives patients a single, trusted point of contact to navigate their treatment journey, from managing appointments and transportation to understanding their diagnosis. The company's services are available to over 10.5 million people, and it manages more than $7 billion in oncology spend. It has demonstrated a 5% to 10% reduction in the total cost of care. Since its launch, the Nashville-based company has achieved significant growth, backed by prominent investors. In September 2026, Thyme Care secured over $125 million in a Series E financing round led by Morgan Health, with participation from Humana and CVS Health Ventures, reaching a valuation of over $2 billion. This funding also marked the establishment of Thyme Companies, a parent entity designed to build a broader portfolio of businesses to address different aspects of the cancer journey.